The blood cancer multiple myeloma, which involves infection-fighting plasma cells in the bone marrow, affects only about 1% of all cancers -- predominantly individuals over age 65. The disease ...

Investigation of DNA Damage Response Genes Validates the Role of DNA Repair in Pediatric Cancer Risk and Identifies SMARCAL1 as a Novel Osteosarcoma Predisposition Gene Multiple myeloma (MM) is ...

Histopathological image of multiple myoloma. Smear preparation of bone marrow aspirate stained with May-Grünwald-Giemsa procedure. It doest not represent a histopathologic image but essentially helps ...

Intensive cytotoxic bridging therapy before B-cell maturation antigen chimeric antigen receptor (CAR) T-cell therapy is associated with prolonged hematopoietic recovery and an increased risk for ...

More than 600 studies and 30+ late-breaking presentations showcase breakthroughs in myeloma and cancer care as 3,000 global experts gather in Toronto. TORONTO--(BUSINESS WIRE)--The International ...

While it’s not as well-known as, say, leukemia or melanoma, multiple myeloma is the second most common blood cancer in adults, according to the Cancer Research Institute. “Multiple myeloma is a cancer ...

Multiple myeloma is a chronic (long-term) blood cancer that affects plasma cells made in the bone marrow, which is spongy tissue found inside bones. While people with multiple myeloma can live for ...

New research shows how curcumin’s molecular power protects bone cells from high-glucose stress, repairs mitochondria, and boosts antioxidant defences, offering hope for tackling diabetes-related bone ...

Panelists highlight advances in myeloma treatment, focusing on innovative T cell therapies like CAR T and T cell engagers, along with potent new CELMoD drugs, all offering more targeted and effective ...

Multiple myeloma is a rare blood cancer of the plasma cells in bone marrow -- the soft, spongy interior of bone where all blood cells are produced. Plasma cells are a type of white blood cell that ...

Disparities in multiple myeloma outcomes are linked to income and geographic location, with lower-income and rural patients experiencing higher mortality rates. Limited access to insurance, novel ...